Anti-PD-1/PD-L1 inhibitor
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-PD-1/PD-L1 inhibitor, covering 2026-02-06 to 2026-02-06. Get the full timeline:
Most recent: Clinical Trial Update: Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies [Phase 1, Phase 2]